Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilovertamab Vedotin in B-cell Malignancies (waveLINE-006)
NCT05458297Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Primary completion
- May 2029
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 2 trial of zilovertamab vedotin in mantle cell lymphoma (MCL), Richter transformation lymphoma (RT), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), sponsored by Merck & Co.. Started Jul 2022; status: active, not recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
mantle cell lymphoma (MCL)Richter transformation lymphoma (RT)follicular lymphoma (FL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05458297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05458297.